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Lymph node target volume delineation
Gastric arteries
D2 resectionPurpose: In the context of gastric cancer, lymph node target volume delineation for post-operative radio-
therapy is currently built on the traditional system of dividing the stomach and 2-D treatment methods.
Here, we have proposed a new delineation approach with irradiation indications for lymph node stations.
Its safety and efﬁcacy were evaluated in a phase II clinical trial.
Materials and methods: Fifty-four gastric cancer patients with D2 lymph node dissection received 2 cycles
of FOLFOX4. They subsequently received concurrent chemoradiotherapy (45 Gy at 1.8 Gy per fraction, 5
fractions per week for 5 weeks) with a 5-ﬂuorouracil/leucovorin regimen, followed by 4 additional
FOLFOX4 cycles. The target volume included the remnant stomach, anastomosis site, tumor bed, and
regional lymph nodes selected through our new approach by taking gastric arteries as references.
Results: The most common grade 3–4 adverse event was neutropenia (14.8%). Neutropenia, anemia, and
nausea were common grade 1–2 toxicities. No treatment-related deaths occurred during treatment. The
3-year overall, disease-free, and locoregional recurrence-free survival rates were 81.6%, 70.2%, and 91.1%,
respectively. Eight patients developed peritoneal or distant metastases.
Conclusions: Using our new approach and irradiation indications, delineation of the target volume of
post-operative lymph node stations was feasible and well tolerated after D2 resection in patients with
gastric cancer.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 245–251
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Gastric cancer is one of the most common malignancies world-
wide, particularly in the Asia–Paciﬁc region [1]. The overall effects
of postoperative treatment remain far from satisfactory [2].
Because of the high locoregional recurrence rates after curative
surgery, postoperative radiotherapy (RT) has been employed as
an adjuvant treatment modality [3]. Although Intergroup Trial
0116 (INT0116) demonstrated that postoperative chemoradiother-
apy (CRT) conferred signiﬁcant survival beneﬁts, this trial has been
criticized because lymph node (LN) dissection was limited (D0 or
D1) in 90% of the enrolled patients [4]. The ARTIST trial investi-
gated postoperative CRT after curative en bloc resection with
extensive (PD2) LN dissection [5]. In this phase III clinical trial,
the addition of RT signiﬁcantly prolonged disease-free survival in
a subgroup of patients with pathologic LN metastasis at the time
of surgery. Currently, postoperative CRT is the standard of carefor locally advanced gastric cancer, at least in North America [3].
Postoperative RT procedures for gastric cancer have also shifted
from simple two-dimensional (2-D) techniques to
three-dimensional (3-D) conformal and intensity-modulated
radiotherapy (IMRT) techniques [6–9].
In 2002, Tepper and Gunderson [3] proposed guidelines for
deﬁning the clinical target volume (CTV) of radiation ﬁelds in cases
of gastric cancer, based on the primary tumor site, T-stage, and
N-stage. In most studies of adjuvant RT for gastric cancer
[5,6,10], the following deﬁnition of RT volume has been applied
without substantial modiﬁcations: primary tumor bed, resection
margins, anastomosis site, duodenal stump, remnant stomach,
and regional LNs. In Tepper and Gunderson’s guidelines, the 2-D
irradiation ﬁeld was determined based on different T- and
N-stage tumors located in the cardia, body, or antrum of the stom-
ach. However, they did not provide detailed indications for the
irradiation of each LN station. Three-dimensional and IMRT tech-
niques are currently in widespread clinical use for postoperative
RT for gastric cancer. Several trials [6,7] have conﬁrmed that
IMRT is well tolerated, safe, and offers reduced damage to normal
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requires more precise target volume delineation, including delin-
eation of the regional gastric LNs. Although recommendations have
been published regarding target volume construction for postoper-
ative gastric cancer, these recommendations have generally been
provided for 2-D techniques. In contrast, such recommendations
are scarce for 3-D computed tomography (CT)-based contouring
of the CTV. Furthermore, detailed indications for the irradiation
of each LN station have not been thoroughly established. Jansen
et al. [11] reported inter-observer variation of CTV delineation in
gastric cancer, ﬁnding that the volumes of CTVs and planning tar-
get volumes (PTVs) differed greatly. Therefore, there is a need for
strict and clear delineation guidelines, as well as indications for
the irradiation of LN stations in postoperative gastric cancer.
The abundance of perigastric LNs and the extensive anastomo-
sis among them make it rather complicated and difﬁcult to deﬁne
each LN station in CT images. The main obstacle is the absence of
relatively ﬁxed references that could be used to deﬁne each LN sta-
tion. In the head and neck area, LN target volume can be deﬁned
based on muscles and fascia [12]. The mediastinal LN area can be
deﬁned from the interspaces between blood vessels [13,14]. The
pelvic LN target volume can be deﬁned by referencing pelvic arter-
ies and veins [15,16]. However, the optimal deﬁnition of the gastric
LN area in CT images has been less clear.
Since the gastric LNs are distributed along the arteries of the
stomach, which have fewer branches and can be easily recognized
in contrast-enhanced CT, we hypothesized that LN target volumes
could be delineated by referencing the gastric arteries in cases of
postoperative gastric cancer. Indeed, the idea of referencing the
gastric arteries corresponds with the LN groupings in the
Japanese classiﬁcation of gastric carcinoma [17]. Further, we
designed detailed indications for the irradiation of each LN station.
Finally, we conducted a phase II clinical trial to evaluate the efﬁ-
cacy and safety of this strategy.Patients and methods
Eligibility criteria
The study was approved by the Medical Ethics Committee of
Zhongnan Hospital of Wuhan University (Hubei, China). All
patients signed informed consent forms before study entry. From
August 2010 to May 2013, patients with gastric cancer were
recruited for this study based on the following eligibility criteria:
performance status of 0–1 (Eastern Cooperative Oncology Group
performance status), histologically conﬁrmed gastric adenocarci-
noma, D2 LN dissection and R0 gastrectomy, no gross peritoneal
seeding evidence during surgical exploration, and no metastatic
disease. All patients had adequate hematologic, hepatic, and renal
function. Patients younger than 18 years; patients with a prior (i.e.,
within 5 years) or synchronous malignancy, other than
non-melanoma skin cancer; and those with signiﬁcant comorbidi-
ties were excluded. Pretreatment evaluations consisted of medical
history assessment; physical examination; hematologic and bio-
chemical analyses; tumor marker evaluations; electrocardiogra-
phy; and CT of the thorax, abdomen (contrast enhanced), and
pelvis. The disease was staged according to the 2002 American
Joint Committee on Cancer (AJCC) staging criteria.Study design and treatment
Eligible patients received 2 cycles of FOLFOX4 (85 mg/m2 oxali-
platin intravenous [IV] infusion on day 1; 200 mg/m2 leucovorin
[LV] IV infusion on days 1–2 in 2 h; 400 mg/m2 5-ﬂuorouracil
[5-FU] IV bolus on days 1–2, followed by 600 mg/m2 5-FU contin-
uous IV infusion in 22 h on days 1–2 every two weeks).Subsequently, they received CRT (45 Gy at 1.8 Gy per fraction, 5
fractions per week for 5 weeks) with a 5-FU/LV regimen
(400 mg/m2 5-FU IV bolus + 20 mg/m2 LV IV bolus per day on the
ﬁrst 4 and the last 3 days of RT), followed by 4 additional cycles
of FOLFOX4.
The chemotherapy was postponed when the absolute neu-
trophil count and platelet count were lower than 1.5  109/L and
100  109/L, respectively, until the counts recovered. The dose of
oxaliplatin could be reduced by 25% after any episode of febrile
neutropenia, grade 4 neutropenia lasting more than 5 days, grade
4 thrombocytopenia, or grade 3 neuropathy. During concurrent
CRT, 5-FU would be reduced by 25% in any case of grade 3 nau-
sea/vomiting, diarrhea, or stomatitis.Radiotherapy techniques and target volume delineation
Fasting patients were maintained in a supine position and
immobilized with vacuum pads. All patients were instructed to
drink 100 mL water. Five minutes later, they underwent the con-
ventional and contrast-enhanced spiral CT scan (Siemens AG,
Munich, German) with a 3-mm slice thickness from the inferior
border of the seventh thoracic vertebra to the inferior border of
the fourth lumbar vertebra. Target volumes consisted of the vol-
umes of the remnant stomach, anastomosis site, tumor bed, and
selected regional LNs. The remnant stomach and anastomosis site
were irradiated in all patients. The tumor bed was covered for
patients with stage T3–4 tumors. The target volume of LN stations
was delineated according to the methods described in the follow-
ing paragraph. The ﬁnal CTVs were generated by uniting the 4 tar-
get volumes. The PTV included the CTV plus margins of 10 mm
superiorly and inferiorly, 7 mm anteriorly and laterally, and
5 mm posteriorly. Three-dimensional CRT or IMRT techniques
were delivered to the patients.Indications for radiation and principals of delineation for the LN target
volume
Based on gastric anatomy, the gastric LN distribution (Fig. 1),
and rules for metastases [17,18], we established radiation indica-
tions and principals of target volume delineation for LNs in cases
of postoperative gastric cancer (Table 1). Fig. 2 provides an illustra-
tive example of the new approach. The important anatomic struc-
ture (Fig. 2A) and the relative CTV (Fig. 2B) of stations 7, 8, 9, 12a,
12p and 16 cranial are delineated in the cross-sectional image of
the celiac artery. The ﬁnal fusion CTV is shown in Fig. 2C.Study endpoints
The primary endpoints were 3-year local–regional
recurrence-free survival (LRFS) and treatment-related toxicity.
The secondary endpoints included 3-year disease-free survival
(DFS) and overall survival (OS). Locoregional recurrence was
deﬁned as any relapse at the remnant stomach, anastomosis site,
tumor bed, or regional LNs. LRFS was calculated from the date of
surgery to the date of ﬁrst locoregional recurrence.
Treatment-related toxicities were assessed according to the
National Cancer Institution Common Terminology Criteria for
Adverse Events (NCI-CTC) version 3.0.Statistical analysis
Survival curves were estimated using the Kaplan–Meier
method. All analyses were performed using SPSS Statistical
Software, version 20.0.
Fig. 1. The 5 anatomical regions of the stomach, as separated according to the arterial supply and the locations of lymph node stations. 1, 2, 3a, 3b, 4sa, 4sb, 4d, 5 and 6
present the perigastric lymph nodes. AGES: A. gastroepiploica sinistra; AGB: Aa. Gastricae breves; APIS: A. phrenica inferior sinistra; VGED: V. gastroepiploica dextra.
Y. Haijun et al. / Radiotherapy and Oncology 116 (2015) 245–251 247Results
From August 2010 to May 2013, 54 patients were enrolled, each
of whom had D2 LN dissection and pathologically proven gastric
adenocarcinoma with LN metastasis. Clinicopathological charac-
teristics are listed in Table 2. The median age was 55 years (range,
25–70 years), and 40 patients (74.1%) were male. According to the
2002 AJCC staging system, 21 (38.8%), 14 (25.9%), 8 (14.8%), and 11
(20.4%) patients had stages II, IIIA, IIIB, and IV (M0) disease,
respectively.
Treatment toxicities and treatment compliance
Fifty-one patients completed the planned protocol. Two
patients failed to complete RT because of severe gastrointestinal
toxicities. One patient refused to accept chemotherapy after con-
current CRT. The toxicities are summarized in Table 3. The most
common grade 3–4 adverse event was neutropenia (14.8%).
Neutropenia, anemia, and nausea were common grade 1–2 toxici-
ties. No treatment-related death occurred during the treatment.Efﬁcacy
During the follow-up period (median, 27 months; range,
8–40 months), locoregional relapse was observed in 3 patients, of
whom 2 developed relapse in local LNs and 1 developed relapse
at the tumor bed. All locoregional relapses occurred within the
radiation ﬁeld. The 3-year LRFS rate was 91.1% (Fig. 3A). Eight
patients developed peritoneal or distant metastasis. The 3-year
DFS and OS rates were 70.2% and 81.6%, respectively
(Fig. 3B and C).
Discussion
In the present study, we proposed a new approach for LN target
volume delineation in the postoperative gastric cancer setting,
based on the locations of LNs relative to the gastric arteries. Our
phase II clinical trial of this approach showed a 3-year LRFS of
91.1%, as well as tolerable and manageable toxicity. Fifty-fourpatients with LN metastatic gastric adenocarcinoma were enrolled,
of whom 51 completed the planned protocol. These preliminary
results indicated that it is feasible to delineate the LN target vol-
ume by using the gastric arteries for reference in patients with
postoperative gastric cancer.
Several studies have examined the efﬁcacy and toxicity of RT for
postoperative gastric cancer. The Intergroup 0116 trial determined
that postoperative CRT was an effective approach for adjuvant
therapy. As compared with surgery alone, adjuvant chemoradia-
tion improved 3-year OS (41% vs. 50%, P < 0.001; median
follow-up, 5 years) [4]. However, high rates of acute toxicity (grade
3+: 41%, grade 4+: 32%) have restricted the clinical application of
adjuvant chemoradiation [4]. Indeed, more than one-sixth of
patients terminated treatment in the Intergroup 0116 trial. The
ARTIST trial showed that, following curative en bloc resection with
extensive (PD2) LN dissection, the addition of RT signiﬁcantly pro-
longed 3-year DFS in a subgroup of patients with pathologic LN
metastasis at the time of surgery. Grade 4 neutropenia occurred
in 5.7% of patients in the XP arm and 4.8% in the XP/XRT/XP arm
[5]. In 2012, Zhu et al. [6] reported that IMRT plus concurrent
chemotherapy improved 5-year recurrence-free survival, as com-
pared with the chemotherapy alone (45.2% vs. 35.8%, P < 0.05).
Our preliminary toxicity and efﬁcacy results are not inferior to
the ﬁndings of these previous studies. Indeed, we observed
3-year LRFS, DFS, and OS rates of 91.1%, 70.2%, and 81.6% respec-
tively. The rate of grade 3–4 adverse events was 14.8%, and only
3 patients (5.8%) failed to complete the treatment. Thus, our strat-
egy appears comparable to the strategies employed in these previ-
ous studies, at least.
Over the past decade, Tepper and Gunderson’s [3] guide for
deﬁning gastric cancer CTVs has been applied in many studies,
including trials and studies of 3-D treatment methods
[5,6,10,19,20]. Nonetheless, detailed CTVs deﬁnitions (especially
for LN stations) have not been clariﬁed for 3-D therapy. In 2013,
Wo et al. [21] reported a consensus LN CTV contouring atlas for
3-D treatment planning. This proposal served as a good template
for delineating gastric LN CTVs. However, the delineations of many
LN stations were based on their locations; the parallel arteries
were infrequently mentioned, which was not consistent with the
Table 1
The radiation indication and principal of target volume delineation for gastric lymph nodes (LNs).
Lymph node station Target volume delineation Radiation indication
1–6 Perigastric LNs Residual stomach and 0.5–1 cm expansion Any perigastric LNs involved
7 LNs along the left gastric
artery
The interspace between the liver and the stomach Lesions occur in the lesser curvature, involve the lower esophagus,
or involve the station 1 or 3a LNsCranial-lower border of the cardia
Caudal-upper border of the celiac trunk
Anterior–anterior border of the lesser gastric curvature
Posterior–anterior border of the abdominal aorta
Right–left border of the liver
Left–right border of the stomach
8 LNs along the common
hepatic artery
The common hepatic artery and 0.5–1 cm expansion Lesions located in the lesser curvature near the pylorus or in the
lower portion of the greater curvature, or involvement to the
station 3b, 5, 6, and 4d lymph nodes
9 LNs around the celiac
artery
The celiac trunk and 0.5–1 cm expansion Any LNs involved
10 LNs at the splenic hilum The splenic artery distal to the pancreatic tail and the vessels
at the splenic hilum, with an additional 0.5–1 cm margin
Lesions at the fundus or the left gastroepiploic artery-supplying
area, or involvement of the 4sa or 4sb LNs
11p Proximal splenic artery
LNs
The splenic artery from its origin to halfway between its
origin and the pancreatic tail end, then with an additional
0.5–1 cm margin
Lesions at the left gastroepiploic artery-supplying area or station 6
LNs involved
11d Distal splenic artery LNs The splenic artery from halfway between its origin and the
pancreatic tail end to the end of the pancreatic tail, then with
an additional 0.5–1 cm margin
Lesions at the fundus or the left gastroepiploic artery-supplying
area
12a Hepatoduodenal
ligament LNs along the
proper hepatic artery
The proper hepatic artery from its gives rise to the left and
right hepatic artery to the common hepatic artery
Lesions at the lesser curvature near the pylorus or at the lower
portion of the greater curvature, or involvement of the station 3b,
5, 6, 4d, and 8 LNs
12p Hepatoduodenal
ligament LNs along the
portal vein
The portal vein from the right hepatic vein joins the portal
vein to the right border of the pancreas
Lesions at the lesser curvature
13 LNs on the posterior
surface of the pancreatic
head
Cranial—the upper border of pancreatic head Signet-ring cell carcinoma or mucinous adenocarcinoma at the
gastric antral, or the pancreas involvedCaudal—the lower border of pancreatic head
Right—the duodenum
Left—the abdominal aorta
Anterior–posterior border of the pancreas
Posterior–anterior border of the inferior vena cava
14v LNs along the superior
mesenteric vein
The superior mesenteric vein from the lower border of the
pancreas to the level of bifurcation of colic vein, then with an
additional 0.5–1 cm margin
Station 6 LNs involved
14a LNs along the superior
mesenteric artery
The proximal 2.5 cm to 3.0 cm of the superior mesenteric
artery and 1 cm expansion
Lesions invading into the adjacent tissues or organs such as the
pancreas or the transverse colon
15 LNs along the middle
colic vessels
The region from the involved transverse colon to the root of
the superior mesenteric vessels
Lesions at the greater curvature and invading into the transverse
colon or its mesentery
16a1* LNs around the
abdominal aorta
Para-aortic LNs in the diaphragmatic aortic hiatus Lesions at gastroesophageal junction
16a2* Cranial: the upper margin of the origin of the celiac artery Any LNs involved
Caudal: the lower border of the left renal vein
16b1* Cranial: the lower border of the left renal vein Any LNs involved, excluding lesions at gastroesophageal junction
Caudal: the upper border of the origin of the inferior
mesenteric artery
16b2* Cranial: the upper border of the origin of the inferior
mesenteric artery
Station 16b2 is generally not included in the CTV
Caudal: the aortic bifurcation
Left: left border of abdominal aorta with an additional 1–1.5 cm margin; Right: right border of abdominal aorta with an additional 2 cm margin; Anterior: anterior border of
abdominal aorta with an additional 1.5–2 cm margin; Posterior: posterior border of abdominal aorta with an additional 0.3–0.5 cm margin.
* 16a1, 16a2, 16b1and16b2 have same left, right, anterior and posterior border
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LN stations based on the corresponding arteries [17]. Further, nei-
ther Wo et al.’s report, nor other studies mentioned indications for
the irradiation of LN stations in 3-D treatment. We attempted to
redeﬁne the delineation of the LN CTV for postoperative gastric
cancer, based on the JGCA deﬁnition of LN station. Moreover, we
have proposed irradiation indications for each LN station, based
on the gastric anatomic structure, rules of lymph drainage, and
relapse characteristics.
The current target deﬁnition for post-operative RT of gastric
cancer is built upon the traditional division system. The traditional
divisions are based on surgical approaches, by which the stomach
is divided into three portions: the fundus (the upper third), the
body (the middle third), and the pylorus (the lower third).
Gastric LN involvement is closely associated with the site of the
primary tumor, making its site indispensable for a proper deﬁni-
tion of gastric portions. However, the traditional division systemdoes not incorporate the rules of lymphatic drainage for the stom-
ach. Since LN are distributed along the corresponding arteries [17],
it is more reasonable to divide the stomach according to its arterial
supply. Accordingly, we proposed to divide the stomach into 5 por-
tions [22]: the left gastric artery-supplying area, the right gastric
artery-supplying area, the short gastric artery-supplying area, the
left gastroepiploic artery-supplying area, and the right gastroepi-
ploic artery-supplying area. There is abundant lymphatic drainage
of the stomach, with extensive anastomosis. Nonetheless, diseases
generally spread from proximal stations to distal stations, and it is
rare for the disease to skip LN metastasis [23]. Based on our new
system of dividing the stomach, we have recommended prophylac-
tic irradiation of LNs belonging to the next station, in addition to
irradiation of metastatic LNs.
There is abundant anastomosis between lymphatic channels in
the submucosal and subserosal layers of the gastric wall.
Consequently, involvement in any single LN group can easily
Fig. 2. The clinical target volume (CTV) delineation in the cross-sectional image of the celiac artery. (A) shows the relative structure, abdominal aorta (green), celiac artery
(blue), common hepatic artery (red), proper hepatic artery (yellow), portal vein (brown), tumor bed (orange), and remnant stomach (pink). (B) presents the relative CTV of the
lymph node station 8 (red), 9 (blue), 12a (yellow), 12p (brown), and 16 cranial (green). The tumor bed (orange) and remnant stomach (pink) are also shown. (C) indicates the
fusion CTV (blue) of the same cross-sectional image of the celiac artery. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
Table 2
Baseline characteristics of the patients.
Characteristics No. patients (%)
Sex Male 40 (74.1)
Female 14 (25.9)
Age (years) Median 55
Range 25–70
ECOG-PS 0 20 (37.0)
1 34 (63.0)
Primary tumor site Proximal 4 (7.4)
Body 22 (40.7)
Antrum 28 (51.9)




Pathologic N status No. of LN (Median) 28
No. of LN (Range) 10–54
No. of positive LN (Median) 5




AJCC stage II 21 (38.8)
IIIA 14 (25.9)
IIIB 8 (14.8)
IV (M0) 11 (20.4)
ECOG PS: Eastern Cooperative Oncology Group Performance Status; LN: lymph
nodes; AJCC: American Joint Committee on Cancer.
Table 3
Treatment-related toxicities.
Toxicity No. patients (%)
Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 12 (22.2) 16 (29.6) 6 (11.1) 2 (3.7)
Thrombocytopenia 6 (11.1) 4 (7.4) 1 (1.9) 0
Anemia 16 (29.6) 12 (22.2) 2 (3.7) 0
Nausea 22 (40.7) 13 (24.1) 3 (5.6) 0
Vomit 13 (24.1) 4 (7.4) 1 (1.9) 0
ALT/AST 3 (5.6) 1 (1.9) 0 0
BUN/Cr 2 (3.7) 1 (1.9) 0 0
Neuropathy 11 (20.3) 2 (3.7) 0 0
ALT/AST: alanine transaminase to aspartate transaminase ratio; BUN/Cr: blood urea
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target volume should always include both the lymphatic channels
inside the gastric wall and perigastric LNs, except for patients withtotal gastrectomy. Because the celiac trunk provides all blood sup-
ply to the stomach, irradiation of LNs around the celiac artery is
also indispensable in any case of LN metastasis.
LNs along the splenic artery (station 11) are further divided into
the proximal half (11p) and the distal half (11d) by the midpoint
between the origin of the splenic artery and the end of the tail of
the pancreas. The 11d LNs receive lymphatic drainage from the
fundus and the upper portion of the greater curvature. In addition
to drainage from 11d LNs, 11p LNs also receive lymphatic drainage
from station 6 LNs [24]. Therefore, irradiation to the 11p LNs
should be considered in cases with involvement of the group 6
LNs at the lower part of the gastric cancer.
The LNs on the posterior surface of the pancreatic head (station
13) receive lymphatic drainage from the posterior region of the
pancreas. They are involved in less than 5% of gastric cancers
[25]. Studies have shown that station 13 LNs are especially likely
to be involved, and should be irradiated in gastric antral cancernitrogen to creatinine ratio.
Fig. 3. (A) Local–regional recurrence-free survival of gastric cancer patients with D2 lymph node dissection and post-operative radiotherapy. (B) Disease-free survival of
gastric cancer patients with D2 lymph node dissection and post-operative radiotherapy. (C) Overall survival of gastric cancer patients with D2 lymph node dissection and
post-operative radiotherapy.
250 Radiotherapy for gastric cancer: a trial[26], cases with positive station 6 LNs [25], signet-ring cell carci-
noma, and mucinous adenocarcinoma.
The 14a LNs are mostly involved in cases with tumor invasion
into the adjacent tissues or organs, such as the pancreas or the
transverse colon. However, the 14v LNs receive lymphatic drai-
nage from station 6 LNs and belong to the group 2 LNs in lower
gastric cancers [27]. The positive rate of station 14v LN metasta-
sis can reach 24% when the station 6 LNs are involved, but this
rate only reaches 1.9% when the station 6 LNs are intact [28].
Thus, the 14v LNs should be irradiated when the station 6 LNs
are involved.
Although the station 16 LNs belong to group 3 LNs, the rate of
their involvement can be as high as 25% and their postoperative
recurrence rate is high [29]. Hence, irradiation of these LNs is rec-
ommended. Station 16 LNs are distributed along the abdominal
aorta and the inferior vena cava. They are divided into the 16a1,
16a2, 16b1, and 16b2 subgroups. The 16a2 and 16b1 subgroup
LNs are most commonly involved, and should be irradiated [30].
Regarding adenocarcinoma at the esophagogastric junction, irradi-
ation of the 16a2 subgroup LNs would be sufﬁcient because the
involvement of 16b1 LNs is rare. The para-aortic LNs involved in
gastric cancer are mainly distributed to the left and anterior of
the abdominal aorta, and in the interspaces between the abdomi-
nal aorta and the inferior vena cava at the level of the left renalvein. In contrast, LNs around the inferior vena cava are not fre-
quently invaded [31].
In the new AJCC staging system for gastric cancer, nodal stage
(N) is based on the number of involved LNs [32], which does not
reﬂect rules of LN metastasis and provides no practical value for
guiding RT target volume delineation. Accordingly, it is more
important to have a detailed understanding of the tumor’s location,
of the LN groups that have been dissected, and of which stations
have been involved. At most institutes, postoperative pathologic
reports currently offer information on tumor location (for example,
in the greater or lesser curvature), but lack detailed information on
the artery supplying area that includes the tumor. Similarly, these
reports describe the dissected LN groups, the total number of
nodes, and the number of positive nodes without further dividing
these nodes into subgroups. In actuality, Supplementary informa-
tion on LN subgroup metastasis is considerably helpful for prophy-
lactic irradiation of the next LN station. To provide more
information on tumor location and LN subgroup involvement,
communication between pathologists and surgical oncologists is
necessary. Preoperative radiographic tests, such as CT scans, can
also be helpful [33].
Special consideration is needed to interpret the results of this
study due to some limitations. Our study is only a phase II, single
arm and non-randomized research, it is necessary to carry out
Y. Haijun et al. / Radiotherapy and Oncology 116 (2015) 245–251 251phase III trials to validate our conclusion. Some patients may not
undergo the contrast-enhanced CT scan for reasons such as allergy
to the contrast agents or renal function insufﬁciency etc., which
makes the contouring of CTV difﬁcult. The difference of epidemiol-
ogy and operation mode of gastric cancer between in East Asia and
western countries may also limit the direct application of our
proposal.
Conclusions
We based our approach for LN target volume delineation on
anatomy, radiology, and rules of gastric lymphatic drainage.
Further, we attempted to maintain consistency with the General
Rules for Gastric Cancer Study in terms of LN target volume nom-
ination and deﬁnition [17]. Finally, we provided irradiation indica-
tions for each LN station. The feasibility and efﬁcacy of our
proposal for delineating the target volume has been demonstrated
by the results of the present phase II clinical trial. When applying
this strategy, adequate consideration should be given to individual
differences between patients. By appropriately combining their
understanding of gastric cancer and previous experience, practi-
tioners should also weigh the advantages and disadvantages of
RT, and thoroughly consider the potential for side effects in impor-
tant organs, such as the liver, kidney, and intestines.
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